Efficacy and Safety of High Dose Baclofen for Alcohol Dependence
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01980706|
Recruitment Status : Completed
First Posted : November 11, 2013
Results First Posted : January 8, 2019
Last Update Posted : June 12, 2019
- Study Details
- Tabular View
- Study Results
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Alcoholism||Drug: Baclofen Drug: Placebo||Phase 2|
Alcohol dependence (AD) is a common problem with significant health consequences. Treatment of AD is evolving to include both counseling methods and medications. Several medications have been discovered, that show efficacy in AD, e.g. naltrexone, acamprosate. However, the overall effect of existing medications is modest leaving a clear need for the development of new pharmacotherapies. The gamma-aminobutyric acid (GABA)-B receptor agonist baclofen has attracted attention as a potential new medication for AD based on preclinical data and early clinical trials. Baclofen is an FDA approved medication with an excellent safety profile even for patients with liver cirrhosis-a not uncommon consequence of AD. Questions have arisen with regards to the efficacy of baclofen and whether higher doses of baclofen are safe and more effective than the prior tested dose of 30 mg/ day. There is emerging evidence that severity of dependence is positively associated with baclofen response. The main goal of the present proposal is to test the efficacy and safety of 30 mg/d and 90 mg/d of baclofen compared to placebo controlling for severity of dependence as assessed by drinks/drinking day. A primary secondary goal will examine for an anxiolytic effect of baclofen. The study proposes to enroll 120 men and women with AD in a randomized, placebo-controlled trial to include at least 60 individuals with more severe AD (≥14 drinks/drinking day for men; ≥10 drinks/drinking day for women) with randomization to baclofen or placebo balanced for this variable. Baclofen will be titrated to 10 mg t.i.d over 3 days and to 30 mg t.i.d over 12 days and maintained at that level for 12 weeks and then downtitrated for a total study time of 16 weeks. Medical Management will be provided to encourage progress towards drinking goals and to enhance retention and compliance. Drinking patterns, anxiety levels, sleep patterns, craving for alcohol, gamma-glutamyl transferase (GGT) and carbohydrate deficient transferring (CDT) will be assessed. Trough blood levels of R & S-baclofen will be assessed in all individuals at week 4.
In summary, the present proposal is innovative and of clinical significance as it will test and compare standard and high-dose baclofen for efficacy and safety in individuals with AD. The proposal is adequately powered to test the primary hypothesis and provides good power to assess whether drinks/drinking day is predictive of baclofen response. Adequate power is also present to examine the anxiolytic effect of baclofen. Ascertaining the effects of standard and high-dose baclofen, the predictive value of heavy drinking on baclofen response and the anxiolytic effect of baclofen are important goals towards determining whether baclofen has true value for the clinical management of the patient with alcohol dependence.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||120 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||Efficacy and Safety of High Dose Baclofen for Alcohol Dependence|
|Actual Study Start Date :||December 12, 2013|
|Actual Primary Completion Date :||October 26, 2017|
|Actual Study Completion Date :||October 26, 2017|
Placebo Comparator: Placebo
Participants will take placebo for 16 weeks, 3 times per day. Placebo will be given in blister packs.
Pill containing no pharmacologically active substance.
Other Name: Sugar pill
Active Comparator: 30 Mg Baclofen
Participants will take baclofen/placebo for 16 weeks, 3 times per day. Baclofen will be given in blister packs. The 30 mg/d arm will reach 30 mg/d at day 3 and titrate down starting at day 101.
Baclofen is a GABA-B agonist
Other Name: Lioresal
Active Comparator: 90 mg Baclofen
Participants will take baclofen/placebo for 16 weeks, 3 times per day. Baclofen will be given in blister packs. The 90 mg/d arm will reach 90 mg/d at day 12 and titrate down starting at day 95.
Baclofen is a GABA-B agonist
Other Name: Lioresal
- Mean Percentage of Heavy Drinking Days [ Time Frame: Every 1-2 weeks up to 16 weeks of active trial ]The frequency of heavy drinking days (5 or more drinks for a man and 4 or more drinks for a woman) as percentage during the treatment phase.
- Mean Percentage of Abstinent Drinking Days [ Time Frame: Every 1-2 weeks up to 16 weeks of active trial ]Percent of abstinent days over the course of the trial.
- Mean Spielberger State-Trait Anxiety Inventory Score [State] [ Time Frame: Every 1-2 weeks up to 16 weeks of active trial ]The Spielberger State and Trait Anxiety Inventory (STAI) is a validated self-reporting instrument used to assess anxiety in adults.The inventory consists of state anxiety, which evaluates how the subject feels currently (transient anxiety). The State scale consists of 20 questions, each question rated 1-4, and a higher score indicates greater anxiety. Total score ranges from 20 (no anxiety) to 80 (maximum anxiety). The scores are averaged over the trial.
- Mean Penn Alcohol Craving Scale Score [ Time Frame: Every 1-2 weeks up to 16 weeks of active trial ]Penn Alcohol Craving Scale (PACS) is a five-item self administered instrument for assessing craving, frequency, intensity, and duration of thoughts about drinking as well as the ability to resist drinking. Scores range from a minimum of zero to a maximum of 30. Lower scores are associated with lower level of craving for alcohol. Scores are averaged over the trial.
- Carbohydrate-deficient Transferrin [ Time Frame: End of trial, generally 16 weeks ]Lab test assessing history of heavy drinking with greater specificity than GGT. Higher levels are indicative of greater levels of drinking.
- Self-reported Sedation on at Least One Occasion by a Participant [ Time Frame: Every 1-2 weeks up to 16 weeks of active trial ]Any reporting of feeling sedated/sleepy/drowsy
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years to 65 Years (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Men and women between the ages of 18 and 65 meeting Diagnostic and Statistical Manual (DSM)-IV criteria for current alcohol dependence.
- More than 14 drinks (women) or 21 drinks (men) per week including at least 2 heavy drinking days (men > 5 drinks/day; women > 4 drinks/day) per week in the 30-day period prior to screening. In addition we will recruit 50% of individuals who have a mean of ≥14 drinks/drinking day (men) or ≥10 drinks/drinking day (women) in the 30 days prior to screening.
- Ability to understand and sign written informed consent.
- Must have a 0.0 gms/dL breathalyzer reading on the day of screening and 0.0 gms/dL on the day of randomization.
- Express a desire to achieve abstinence or to greatly reduce alcohol consumption
- Must have a stable residence and be able to identify an individual who could contact participant if needed.
- Clinically significant medical disease that might interfere with the evaluation of the study medication or present a safety concern (e.g., renal insufficiency, cirrhosis, unstable hypertension, diabetes mellitus, seizure disorder). Clinically significant psychiatric illness including any psychotic disorder, bipolar disorder, severe depression, or suicidal ideation.
Other substance abuse or dependence disorder other than nicotine or alcohol or cannabis abuse.
Occasional use of cocaine is acceptable.
- Concurrent use of any psychotropic medication including antidepressants, mood stabilizers, antipsychotics, anxiolytics, stimulants, or hypnotics with the exception of stable doses of antidepressants for one month. Concurrent use of anticonvulsants, insulin, or oral hypoglycemics.
- Prior history of adverse reaction to baclofen.
- Creatinine level > Upper Limit of Normal (ULN) or Estimated Glomerular Filtration Rate < age norm.
- aspartate aminotransferase (AST), or alanine transaminase (ALT) > 5 times ULN or bilirubin > 1.5 X ULN.
- Positive urine toxicology screen with the exception of cannabis. Individuals with positive cannabis screens will be excluded only if they have a history of cannabis dependence.
- Pregnant women and women of childbearing potential who do not practice a medically acceptable form of birth control (oral or depot contraceptive, or barrier methods such as diaphragm or condom with spermicidal).
- Women who are breastfeeding.
- Individuals requiring inpatient treatment or more intense outpatient treatment for their alcohol dependence.
- Participation in any clinical trial within the past 60 days.
- Court-mandated participation in alcohol treatment or pending incarceration.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01980706
|United States, North Carolina|
|University of North Carolina at Chapel Hill|
|Chapel Hill, North Carolina, United States, 27599|
|Principal Investigator:||James C Garbutt, MD||University of North Carolina|
Documents provided by University of North Carolina, Chapel Hill:
|Responsible Party:||University of North Carolina, Chapel Hill|
|Other Study ID Numbers:||
4R01AA020824-04 ( U.S. NIH Grant/Contract )
|First Posted:||November 11, 2013 Key Record Dates|
|Results First Posted:||January 8, 2019|
|Last Update Posted:||June 12, 2019|
|Last Verified:||October 2018|
Muscle Relaxants, Central
Physiological Effects of Drugs
Peripheral Nervous System Agents
GABA-B Receptor Agonists
Molecular Mechanisms of Pharmacological Action